STOCK TITAN

Praxis Precision Medicines to Present at Two February Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in two upcoming investor conferences in February 2025.

The company will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotechnology Conference in New York City on February 6, 2025, at 2:30 p.m. EST, and at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11, 2025, at 11:20 a.m. EST.

One-on-one meetings with investors will be available during both conferences through respective representatives. Live webcasts will be accessible through provided links and the company's website, with replays available for 90 days under the 'Events and Presentations' page in the 'Investors + Media' section.

Praxis Precision Medicines (NASDAQ: PRAX), una società biopharmaceutica in fase clinica focalizzata nello sviluppo di terapie per i disturbi del SNC, ha annunciato la sua partecipazione a due conferenze per investitori in programma per febbraio 2025.

La società parteciperà a un colloquio informale al Guggenheim Securities SMID Cap Biotechnology Conference a New York City il 6 febbraio 2025, alle 14:30 EST, e all'Oppenheimer 35th Annual Healthcare Life Sciences Conference, che si svolgerà virtualmente l'11 febbraio 2025, alle 11:20 EST.

Incontri individuali con investitori saranno disponibili durante entrambe le conferenze tramite i rappresentanti rispettivi. Saranno accessibili webcast in diretta tramite i link forniti e attraverso il sito web dell'azienda, con repliche disponibili per 90 giorni nella pagina 'Eventi e Presentazioni' nella sezione 'Investitori + Media'.

Praxis Precision Medicines (NASDAQ: PRAX), una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias para trastornos del SNC, ha anunciado su participación en dos próximas conferencias para inversores en febrero de 2025.

La compañía participará en una charla informal en la Guggenheim Securities SMID Cap Biotechnology Conference en Nueva York el 6 de febrero de 2025, a las 2:30 p.m. EST, y en la Oppenheimer 35th Annual Healthcare Life Sciences Conference, que se llevará a cabo de manera virtual el 11 de febrero de 2025, a las 11:20 a.m. EST.

Las reuniones uno a uno con inversores estarán disponibles durante ambas conferencias a través de los respectivos representantes. Se podrán acceder a las transmisiones en vivo a través de los enlaces proporcionados y en la página web de la empresa, con repeticiones disponibles durante 90 días en la sección 'Eventos y Presentaciones' dentro de 'Inversores + Medios'.

프락시스 프리시전 메디슨스 (NASDAQ: PRAX)는 CNS 질환 치료제 개발에 집중하는 임상 단계의 생명공학 회사로, 2025년 2월 두 개의 투자자 컨퍼런스에 참여할 예정이라고 발표했습니다.

회사는 2025년 2월 6일 오후 2시 30분 EST에 뉴욕에서 열리는 구겐하임 증권 SMID 캡 생명공학 컨퍼런스에서 파이어사이드 채팅에 참여하고, 2025년 2월 11일 오전 11시 20분 EST에 가상으로 열리는 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참석합니다.

양쪽 컨퍼런스에서 각 대표를 통해 투자자와의 일대일 회의가 가능할 것입니다. 라이브 웹캐스트는 제공된 링크와 회사 웹사이트를 통해 접근할 수 있으며, '투자자 + 미디어' 섹션의 '이벤트 및 발표' 페이지에서 90일 동안 다시 볼 수 있습니다.

Praxis Precision Medicines (NASDAQ: PRAX), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour les troubles du SNC, a annoncé sa participation à deux conférences pour investisseurs prévues en février 2025.

La société participera à une discussion informelle lors de la Guggenheim Securities SMID Cap Biotechnology Conference à New York le 6 février 2025 à 14h30 EST, et à la Oppenheimer 35th Annual Healthcare Life Sciences Conference, qui se déroulera virtuellement le 11 février 2025 à 11h20 EST.

Des réunions individuelles avec les investisseurs seront disponibles lors des deux conférences par l'intermédiaire des représentants respectifs. Des webcasts en direct seront accessibles via les liens fournis et le site web de la société, avec des rediffusions disponibles pendant 90 jours sur la page 'Événements et Présentations' dans la section 'Investisseurs + Médias'.

Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für ZNS-Erkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Februar 2025 angekündigt.

Das Unternehmen wird an einem Fireside-Chat auf der Guggenheim Securities SMID Cap Biotechnology Conference in New York City am 6. Februar 2025 um 14:30 Uhr EST teilnehmen und an der Oppenheimer 35th Annual Healthcare Life Sciences Conference, die am 11. Februar 2025 um 11:20 Uhr EST virtuell stattfinden wird.

Einzelgespräche mit Investoren werden während beider Konferenzen über die jeweiligen Vertreter verfügbar sein. Live-Webcasts werden über die bereitgestellten Links und die Website des Unternehmens zugänglich sein, mit Aufzeichnungen, die für 90 Tage im Abschnitt 'Veranstaltungen und Präsentationen' der Kategorie 'Investoren + Medien' verfügbar sind.

Positive
  • None.
Negative
  • None.

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences:

  • Praxis management will be participating in a fireside chat at the Guggenheim Securities SMID Cap Biotechnology Conference, taking place in New York City on February 6, 2025, at 2:30 p.m. EST. A live webcast of the event will be available through this link.
  • Praxis management will also be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11, 2025, at 11:20 a.m. EST. A live webcast of the event will be available through this link.

The Company will be available for one-on-one meetings during both conferences. Interested investors should contact their respective Guggenheim and/or Oppenheimer representatives to request meetings.

Both webcasts will also be available on the “Events and Presentations” page under the “Investors + Media” section of the company’s website. A replay of the webcasts will be available for 90 days.

About Praxis  
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on FacebookLinkedIn and Twitter/X.


FAQ

When is Praxis Precision Medicines presenting at the Guggenheim Securities Conference in February 2025?

Praxis Precision Medicines will present at the Guggenheim Securities SMID Cap Biotechnology Conference on February 6, 2025, at 2:30 p.m. EST in New York City.

What is the date and time for PRAX's presentation at the Oppenheimer Healthcare Conference?

PRAX will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference virtually on February 11, 2025, at 11:20 a.m. EST.

How long will the PRAX investor conference webcasts be available for replay?

The webcasts from both investor conferences will be available for replay for 90 days on the company's website.

How can investors arrange one-on-one meetings with PRAX management at the February 2025 conferences?

Investors interested in one-on-one meetings should contact their Guggenheim and/or Oppenheimer representatives to request meetings.

Where can investors access the live webcasts of PRAX's February 2025 conference presentations?

Investors can access the live webcasts through provided links and on the 'Events and Presentations' page under the 'Investors + Media' section of Praxis's website.

Praxis Precision Medicines, Inc.

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Stock Data

1.61B
17.29M
0.25%
106.86%
10.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON